Realities of contraceptive factors as protectors against the development of cervical cancer due to HPV
Keywords:
HPV, papilloma, contraceptives, contraception, cervical cancer, cervical cancer.Abstract
Cervical cancer in Latin America continues to be an alarming and worrying reason for women’s mortality. Its association with the human papillomavirus is increasingly clearer, as well as sociocultural factors determine this scourge. A systematic literature search was conducted in the main databases, focusing on the relationship between the virus, its main serotypes, and hormonal and non-hormonal contraceptive methods. In conclusion, the mechanisms of contraceptives can modify the natural history of HPV infection and the development of cervical cancer, due to local changes in the cervix and alterations in host-virus dynamics, although regarding some such as the IUD there is still debate; As for the condom, it is described that its use decreases the risk of HPV infection and progression of precancerous lesions.
References
La colposcopia y el tratamiento de la neoplasia intraepitelial cervical: Manual para principiantes. Gov.co. 2022. Disponible en: https://screening.iarc.fr/doc/colpoesmanual.pdf
Human Papillomavirus and Related Diseases Report World. 2020. Available from: https://hpvcentre.net/statistics/reports/XWX.pdf.
Guías de Practicas esenciales Control Integral CaCu 2da Ed. WHO/OPS). https://revistamedica.com/generalidades-cancer-cervicouterino/
Ayala Luna S, & Delgado N, Fisterra M. 2017. Disponible en: http://www.fisterra.com/guias-clinicas/prevencion-cancer-cuello-uterino). https://revistamedicasinergia.com/index.php/rms/article/download/300/672?inline=1
Rey-Ares L. Eficacia y seguridad de la vacuna contra el virus de papiloma humano para la prevención del cáncer de cuello uterino: revisión sistemática y metaanálisis. Archivos Argentinos de Pediatría. 2012;110(6):483–9. Available from: https://www.sap.org.ar/docs/publicaciones/archivosarg/2012/v110n6a05.pdf.
Hull R, Mbele M, Makhafola T, Hicks C, Wang S, Reis RM. et al. Cervical cancer in low and middle-income countries (Review). Oncology Letters. 202;20:2058-2074. https://doi.org/10.3892/ol.2020.11754.
The nobel commcomite for physiology or medicine 2008, Ilustración Annika Rohi. https://genolifeadn.com/deteccion-del-virus-del-papiloma-humano/
Ochoa FJ, Guarneros DB, Velasco MT. Infección por virus del papiloma humano en mujeres y su prevención. Cirugía oncológica, Instituto Nacional de Cancerología de México. México Grupo Oncológico, Hospital Ángeles del Pedregal. México. (https://www.elsevier.es/es-revista-gaceta-mexicana-oncologia-305-articulo-infeccion-por-virus-del-papiloma-S1665920115000607)
Sarid R, Gao SJ. Viruses and human cancer: from detection to causality. Cancer Lett. 2011;305(2):218-27.
Ministerio de Salud y Protección Social: Dirección de Promoción y Prevención Subdirección de enfermedades transmisibles Grupo de Enfermedades Inmunoprevenibles Gov.co. 2022. Disponible en: https://www.minsalud.gov.co/salud/Documents/Lineamientos%20VPH.pdf.
División of STD Prevention. Virus del papiloma humano: Información sobre el VPH para los médicos. 2007. Available from: https://www.minsalud.gov.co/salud/Documents/observatorio_vih/documentos/literatura_interes/Virus%20del%20papiloma%20humano.pdf.
Salazar L, González L, Olmos A, Calzada L. Influencia del uso de anticonceptivos orales como factores de riesgo para infección por virus del papiloma humano y neoplasia intraepitelial cervical hpps://www.medigraphic.com/pdfs/ginobsmex/gom-2005/gom052e.pdf)
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550-60.
Hiller T, Iftner T. The human papillomavirus. In: Prendiville W, Davies P, editors. HPV Handbook. London, U.K.: Taylor & Francis Group; 2004:11-26.
Ikenberg H. Laboratory diagnosis of human papillomavirus infection. Curr Probl Dermatol. 2014;45:166–74. Available from: https://www.karger.com/DOI/10.1159/000356515.
Semba M, Mori N. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol Rev. 2012;6:e17. doi: 10.4081/oncol.2012.e17.
Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, et al. Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem. 2007;282(38):27913-22.
Picconi MA, Alonio LV, Garcia A, Lizano M, Cervantes G, Distefano AL, et al. Molecular variants of human papillomavirus (HPV) types 16 and 18 in adenocarcinomas of the cervix. Medicina. 2000;60(6):889-94.
De Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17-27.
Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, et al. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more: HPV genotyping for risk stratification. Int J Cancer. 2018;143(2):333–42. Available from: http://dx.doi.org/10.1002/ijc.31326.
Al Bitar S, Ballouz T, Doughan S, Gali-Muhtasib H, Rizk N. Potential role of micro ribonucleic acids in screening for anal cancer in human papilloma virus and human immunodeficiency virus related malignancies. World J Gastrointest Pathophysiol. 2021;12(4):59–83. Available from: http://dx.doi.org/10.4291/wjgp.v12.i4.59.
Morgan K, Azzani M, Khaing SL, Wong Y-L, Su TT. Acceptability of Women Self-Sampling versus Clinician-Collected Samples for HPV DNA Testing: A Systematic Review. Journal of Lower Genital Tract Disease. 2019;23(3):193–9.
Wielgosz AA, Pietrzak B. Human papilloma virus-related premalignant and malignant lesions of the cervix and anogenital tract in immunocompromised women. Ginekol Pol. 2020;91(1):32–7. Disponible en: https://journals.viamedica.pl/ginekologia_polska/article/view/GP.2020.0008/50137
Santiago P, Moncayo B, Fabricio J, Zambrano M. Sec.es. Preferencias Anticonceptivas En Pacientes Atendidas En Consulta Externa Del Hospital Metropolitano De Quito Desde Enero A Noviembre Del 2019. 2022. Disponible en: http://hosting.sec.es/Memorias_Master/IB/temas/Consejo%20contraceptivo/Bravo_Macias.pdf.
Rodríguez MJ. Anticoncepción y prevención de infecciones de transmisión sexual en la adolescencia. An Pediatr Contin. 2014;12(6):362–5. Disponible en: https://www.elsevier.es/es-revista-anales-pediatria-continuada-51-articulo-anticoncepcion-prevencion-infecciones-transmision-sexual-S1696281814702185.
Planificación familiar: conocimiento y uso de métodos. Encuesta Nacional de Demografía y Salud 2010. Bogotá. 2011:32. Disponible en: http://uvsalud.univalle.edu.co/pdf/plan_desarrollo/capitulo-6.pdf.
Crow JM. HPV: The global burden. Nature. 2012;488(7413):S2-3.
Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995;69(12):7743-53.
Burk RD, Chen Z, Harari A, Smith BC, Kocjan BJ, Maver PJ, et al. Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta Dermatovenerol Alp Panonica Adriat. 2011;20(3):113-23.
Volpato LK, Siqueira IR, Nunes RD, Piovezan AP. Association between Hormonal Contraception and Injuries Induced by Human Papillomavirus in the Uterine Cervix. Revista Brasileira de Ginecología e Obstetricia. 2018;40:196–202. Available from:https://www.scielo.br/j/rbgo/a/MYk6wNXx37gfCnkPnNwThph/?lang=en).
Deese J, Pradhan S, Goetz H, Morrison C. Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives. Open Access J Contracept. 2018;9:91 Disponible en: https://www.dovepress.com/contraceptive-use-and-the-risk-of-sexually-transmitted-infection-syste-peer-reviewed-fulltext-article-OAJC
FSRH clinical guideline: Combined hormonal contraception (January 2019, amended November 2020). Fsrh.org. 2022. Available from: https://www.fsrh.org/standards-and-guidance/documents/combined-hormonal-contraception/.
Shibata T, Nakagawa M, Coleman HN, Owens SM, Greenfield WW, Sasagawa T, et al. Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota. PLoS One. 2021;16(8):e0237556. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237556
FSRH clinical guideline: Progestogen-only implant (February 2021). Fsrh.org. 2022. Available from: https://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-implants-feb-2014.
Tough DeSapri K, Batur P. Contraception update: Prevention of gynecologic malignancies and mood benefits. J Womens Health (Larchmt). 2021;30(5):642–5. Disponible en: http://dx.doi.org/10.1089/jwh.2020.8883
Averbach SH, Ma Y, Smith-McCune K, Shiboski S, Moscicki AB. The effect of intrauterine devices on acquisition and clearance of human papillomavirus. Am J Obstet Gynecol. 2017;216(4):386.e1-386.e5. Disponible en: http://dx.doi.org/10.1016/j.ajog.2016.11.1053.
Vásquez-Awad AMO. Anticonceptivos Orales. 2020; Suplemento Ginecol Obstet Mex. 2020;88(Supl1):S13-S31. Disponible en: https://www.medigraphic.com/pdfs/ginobsmex/gom-2020/goms201d.pdf.
González Fernández C, Fernández Revilla JM. Manejo de los Implantes Subdérmicos de Etonogestrel en Atención Primaria. Rev clín med fam. 2011;4(2). Available from: https://scielo.isciii.es/pdf/albacete/v4n2/especial5.pdf.
Villalobos-Sánchez M. Relación Entre El Dispositivo Intrauterino Y La Neoplasia Cervical. Sinergia. 2017;2(11)7–12.
Soriano H, Rodenas L, Moreno D. Criterios de Elegibilidad de Métodos Anticonceptivos: Nuevas Recomendaciones. Rev clín med fam. 2010;3(3):206–16. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-695X2010000300009.
Capella S, Daniela, et al. “Criterios Médicos de Elegibilidad Para El Uso de Anticonceptivos de La OMS.” Revista Chilena de Obstetricia Y Ginecología. 2017;82(2)212–218. scielo.conicyt.cl/scielo.php?pid=S0717-75262017000200012&script=sci_arttext&tlng=p, 10.4067/S0717-75262017000200012.
Virus del papiloma humano en cinco regiones de Colombia: una realidad latente. 1Library.co. 2022. Disponible en: https://1library.co/document/ky600mgy-virus-papiloma-humano-cinco-regiones-colombia-realidad-latente.html
Vacunación contra el VPH en Colombia. De la pesadilla a un resplandeciente y prometedor amanecer. Liga Colombiana contra el Cáncer. 2020. Disponible en: https://www.ligacancercolombia.org/noticias/vacunacion-contra-el-vph-en-colombia-de-la-pesadilla-a-un-resplandeciente-y-prometedor-amanecer/
Lineamientos Para la Gestión y Administración del Programa Ampliado de Inmunizaciones -PAI -2022. Gov.co. 2022. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/PAI/lineamientos-nal-pai-2022.pd
Downloads
Published
Versions
- 2025-11-19 (4)
- 2025-11-19 (3)
- 2025-08-13 (2)
- 2022-04-25 (1)
How to Cite
Issue
Section
License
Copyright (c) 2022 Scientific and Eduaction Medical JournalAtribución – No comercial – Compartir igual: Esta licencia permite a otros distribuir, remezclar, retocar, y crear a partir de tu obra de modo no comercial, siempre y cuando te den crédito y licencien sus nuevas creaciones bajo las mismas condiciones.
Attribution-NonCommercial-ShareAlike 4.0 International
